Allianz Asset Management GmbH Sells 2,199 Shares of Illumina, Inc. (NASDAQ:ILMN)

Allianz Asset Management GmbH decreased its position in Illumina, Inc. (NASDAQ:ILMNFree Report) by 9.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,308 shares of the life sciences company’s stock after selling 2,199 shares during the quarter. Allianz Asset Management GmbH’s holdings in Illumina were worth $2,967,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Annis Gardner Whiting Capital Advisors LLC purchased a new position in Illumina during the third quarter worth about $30,000. VisionPoint Advisory Group LLC boosted its stake in shares of Illumina by 344.6% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock worth $34,000 after buying an additional 193 shares during the last quarter. Wetzel Investment Advisors Inc. bought a new position in shares of Illumina in the fourth quarter valued at approximately $37,000. Gradient Investments LLC increased its position in shares of Illumina by 375.0% during the fourth quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock valued at $40,000 after acquiring an additional 225 shares during the last quarter. Finally, North Star Investment Management Corp. lifted its holdings in Illumina by 183.0% during the fourth quarter. North Star Investment Management Corp. now owns 300 shares of the life sciences company’s stock worth $42,000 after acquiring an additional 194 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. OTR Global restated a “mixed” rating on shares of Illumina in a research note on Wednesday, March 20th. Jefferies Financial Group initiated coverage on shares of Illumina in a report on Monday, June 3rd. They set a “hold” rating and a $115.00 price objective for the company. TD Cowen dropped their target price on shares of Illumina from $140.00 to $122.00 and set a “hold” rating on the stock in a research note on Thursday. StockNews.com raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, May 11th. Finally, Stephens reaffirmed an “overweight” rating and issued a $170.00 price target on shares of Illumina in a report on Tuesday, May 7th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $161.24.

View Our Latest Report on ILMN

Illumina Trading Down 0.9 %

Shares of Illumina stock opened at $113.70 on Friday. The company’s 50-day moving average price is $116.80 and its 200-day moving average price is $126.94. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. Illumina, Inc. has a 12-month low of $89.00 and a 12-month high of $212.49. The company has a market cap of $18.11 billion, a price-to-earnings ratio of -13.95 and a beta of 1.20.

Illumina (NASDAQ:ILMNGet Free Report) last posted its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.05. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.05 billion. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The business’s revenue for the quarter was down 1.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.08 EPS. On average, equities analysts expect that Illumina, Inc. will post 0.88 earnings per share for the current fiscal year.

Illumina Profile

(Free Report)

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Featured Stories

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMNFree Report).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.